| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045851299 |
| P356 | DOI | 10.1038/SJ.ONC.1205650 |
| P698 | PubMed publication ID | 12149650 |
| P5875 | ResearchGate publication ID | 11232409 |
| P2093 | author name string | Jie Zhang | |
| Hong Yu | |||
| J Silvio Gutkind | |||
| Yong Choi | |||
| Brett P Monia | |||
| Cristina Murga | |||
| Erich Koller | |||
| Weiqun Li | |||
| P2860 | cites work | The lipid phosphatase activity of PTEN is critical for its tumor supressor function | Q22007981 |
| Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor | Q22009126 | ||
| Regulation of endothelium-derived nitric oxide production by the protein kinase Akt | Q22010149 | ||
| Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation | Q22010150 | ||
| SH2-containing inositol 5'-phosphatase SHIP2 associates with the p130(Cas) adapter protein and regulates cellular adhesion and spreading | Q24290742 | ||
| Mechanism of activation of protein kinase B by insulin and IGF-1 | Q24309528 | ||
| The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 | ||
| Phosphorylation and activation of p70s6k by PDK1 | Q24323433 | ||
| 3-Phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase | Q24336639 | ||
| Phosphorylation of Ser-241 is essential for the activity of 3-phosphoinositide-dependent protein kinase-1: identification of five sites of phosphorylation in vivo | Q24531714 | ||
| A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region | Q48205638 | ||
| Xid-like immunodeficiency in mice with disruption of the p85alpha subunit of phosphoinositide 3-kinase. | Q52533403 | ||
| Impaired B cell development and proliferation in absence of phosphoinositide 3-kinase p85alpha. | Q52533405 | ||
| Negative regulation of the forkhead transcription factor FKHR by Akt. | Q52535267 | ||
| RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. | Q54068798 | ||
| High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice | Q58378937 | ||
| Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyperresponsiveness to CD3 stimulation | Q24550768 | ||
| The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase | Q24567715 | ||
| Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B | Q27860731 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| Signalling through the lipid products of phosphoinositide-3-OH kinase | Q28241516 | ||
| Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP | Q28254532 | ||
| Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt | Q28255373 | ||
| p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity | Q28280824 | ||
| The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity | Q28289470 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN | Q28513537 | ||
| The lipid phosphatase SHIP2 controls insulin sensitivity | Q28584843 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span | Q28590421 | ||
| Shc interaction with Src homology 2 domain containing inositol phosphatase (SHIP) in vivo requires the Shc-phosphotyrosine binding domain and two specific phosphotyrosines on SHIP | Q28609044 | ||
| Phosphorylation of the transcription factor forkhead family member FKHR by protein kinase B | Q28638147 | ||
| Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B | Q28646376 | ||
| New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway | Q29616144 | ||
| Phosphoinositide kinases | Q29618047 | ||
| The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase | Q29618387 | ||
| The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells | Q30472928 | ||
| The role of phosphoinositide 3-kinase lipid products in cell function | Q33543235 | ||
| The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway | Q33599964 | ||
| Recent advances in the treatment of multiple myeloma | Q33684182 | ||
| Protein kinase C-delta is an important signaling molecule in insulin-like growth factor I receptor-mediated cell transformation | Q33780757 | ||
| The multiple roles of PTEN in tumor suppression | Q33849727 | ||
| 5' phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells | Q33965618 | ||
| Update on the treatment of multiple myeloma | Q34221383 | ||
| Differential regulation of B cell development, activation, and death by the src homology 2 domain-containing 5' inositol phosphatase (SHIP) | Q36404338 | ||
| Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain | Q36818855 | ||
| A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. | Q40020748 | ||
| SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival | Q40443155 | ||
| SHIP modulates immune receptor responses by regulating membrane association of Btk. | Q41042940 | ||
| The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis | Q41116808 | ||
| Experimental plasmacytomagenesis in mice | Q41460441 | ||
| The inositol polyphosphate 5-phosphatase ship is a crucial negative regulator of B cell antigen receptor signaling | Q42462089 | ||
| Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. | Q42824933 | ||
| Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression | Q43806330 | ||
| P433 | issue | 34 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5289-5300 | |
| P577 | publication date | 2002-08-01 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells | |
| P478 | volume | 21 |
| Q34781122 | A framework for genomic biomarker actionability and its use in clinical decision making |
| Q38218256 | AKT as a therapeutic target in multiple myeloma |
| Q46965394 | Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease |
| Q57478281 | An Apoptotic and Endosymbiotic Explanation of the Warburg and the Inverse Warburg Hypotheses |
| Q30843245 | BPOZ-2 directly binds to eEF1A1 to promote eEF1A1 ubiquitylation and degradation and prevent translation |
| Q82057263 | Cancer |
| Q35198905 | Caspase-mediated cell death in hematological malignancies: theoretical considerations, methods of assessment, and clinical implications |
| Q35631315 | Defining the role of TORC1/2 in multiple myeloma |
| Q38018345 | Do annexins participate in lipid messenger mediated intracellular signaling? A question revisited. |
| Q40355713 | Expression of Akt (protein kinase B) and its isoforms in malignant lymphomas. |
| Q37880074 | From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma |
| Q39877920 | Glutathione peroxidase-1 regulates mitochondrial function to modulate redox-dependent cellular responses |
| Q35828537 | Hepatitis B virus X protein induces expression of alpha-fetoprotein and activates PI3K/mTOR signaling pathway in liver cells. |
| Q33717222 | High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886) |
| Q41971722 | Inhibition of transfected PTEN on human colon cancer |
| Q37820689 | Inhibitor and activator: dual functions for SHIP in immunity and cancer |
| Q36438742 | Lipid phosphatases as drug discovery targets for type 2 diabetes. |
| Q35157985 | Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders |
| Q40420617 | Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. |
| Q34180961 | Mechanisms by which IGF-I may promote cancer |
| Q40529674 | Microenvironment factors do not afford myeloma cell lines protection from simvastatin |
| Q40376614 | Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. |
| Q40397686 | N-benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells |
| Q36197104 | Neuronal Cbl controls biosynthesis of insulin-like peptides in Drosophila melanogaster. |
| Q38379348 | Oncogenic and Therapeutic Targeting of PTEN Loss in Bone Malignancies |
| Q39380262 | Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype |
| Q40250832 | PTEN modulates hepatitis B virus-X protein induced survival signaling in Chang liver cells |
| Q42816027 | PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes |
| Q38879505 | Pharmacodynamics and pharmacokinetics of inositol(s) in health and disease |
| Q42178173 | Pharmacological targeting of phosphoinositide lipid kinases and phosphatases in the immune system: success, disappointment, and new opportunities |
| Q42400150 | Phase IB study of cabozantinib in patients with relapsed and/or refractory multiple myeloma |
| Q36461618 | Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia. |
| Q44588841 | Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway |
| Q44548869 | Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line |
| Q45099758 | Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen |
| Q34629544 | SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer |
| Q24338807 | SH2-containing 5'-inositol phosphatase, SHIP2, regulates cytoskeleton organization and ligand-dependent down-regulation of the epidermal growth factor receptor |
| Q49972870 | SHIP negatively regulates type II immune responses in mast cells and macrophages |
| Q24296643 | SHIP2 interaction with the cytoskeletal protein Vinexin |
| Q55086372 | Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. |
| Q36727713 | Six1 induces protein synthesis signaling expression in duck myoblasts mainly via up-regulation of mTOR |
| Q40612882 | Slit protein-mediated inhibition of CXCR4-induced chemotactic and chemoinvasive signaling pathways in breast cancer cells |
| Q38971845 | Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib |
| Q37950586 | Targeting the bone marrow in Waldenstrom macroglobulinemia. |
| Q33577824 | The role of the PTEN/PI3K/Akt pathway on prognosis in epithelial ovarian cancer: a meta-analysis |
| Q35147412 | The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases |
| Q35824929 | The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery |
| Q37702186 | Type I insulin-like growth factor receptor signaling in hematological malignancies |
| Q38271796 | Understanding the tumor suppressor PTEN in chronic alcoholism and hepatocellular carcinoma |
Search more.